Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2014 Oct;26(10):648-52.
doi: 10.1016/j.clon.2014.05.012. Epub 2014 Jun 12.

R-CHOP versus R-COMP: are they really equally effective?

M Mian  1 , I Wasle  2 , G Gamerith  2 , P Mondello  3 , T Melchardt  4 , T Jäger  5 , W Linkesch  6 , M Fiegl  2
Affiliations
Comparative Study

R-CHOP versus R-COMP: are they really equally effective?

M Mian et al. Clin Oncol (R Coll Radiol). 2014 Oct.

Abstract

The first-line standard treatment for diffuse large B-cell lymphoma (DLBCL) is the R-CHOP regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone). It is associated with cardiotoxicity, which is why new treatment strategies are needed. Liposomial doxorubicin has been proven to reduce these side-effects, but until now a direct comparison regarding efficacy has not yet been published. We retrospectively assessed 364 consecutive DLBCL patients who underwent either R-CHOP (218; 60%) or R-COMP (doxorubicin replaced by non-pegylated liposomal doxorubicin; 146; 40%) in first line and compared outcome and survival. We provide evidence that both regimens induce a high and comparable number of complete remissions and that both are able to cure patients with DLBCL. Confirmatory data are needed.

Keywords: Diffuse large B-cell lymphoma; R-CHOP; R-COMP; outcome.

PubMed Disclaimer

Publication types

MeSH terms

LinkOut - more resources